BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.43 USD | -1.44% |
|
-3.40% | -22.81% |
Financials (USD)
| Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 14.34B |
|---|---|---|---|---|---|
| Net income 2024 * | 363M | Net income 2025 * | 504M | EV / Sales 2024 * | 4.98 x |
| Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.21 x |
| P/E ratio 2024 * |
41.2
x | P/E ratio 2025 * |
29.2
x | Employees | 3,401 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioMarin Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | -1.44% | ||
| 1 week | -3.40% | ||
| Current month | -7.84% | ||
| 1 month | -8.01% | ||
| 3 months | -17.92% | ||
| 6 months | -15.99% | ||
| Current year | -22.81% |
1 week
74.09
78.20
1 month
74.0985.04
Current year
74.0999.25
1 year
74.0999.56
3 years
70.73117.77
5 years
62.88131.95
10 years
55.36151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
C. Guyer
CTO | Chief Tech/Sci/R&D Officer | 62 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Elaine Heron
BRD | Director/Board Member | 76 | 02-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | -0.95% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 74.43 | -1.44% | 2,863,060 |
| 24-05-24 | 75.52 | -0.50% | 2,028,948 |
| 24-05-23 | 75.9 | -0.72% | 2,859,280 |
| 24-05-22 | 76.45 | -1.15% | 2,746,523 |
| 24-05-21 | 77.34 | +0.38% | 1,837,649 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.52
USD
Average target price
109.3
USD
Spread / Average Target
+44.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.81% | 14.34B | |
| -1.64% | 90.28B | |
| -1.97% | 39.5B | |
| -15.47% | 31.71B | |
| +61.28% | 26.41B | |
| -8.82% | 12.89B | |
| -11.77% | 11.8B | |
| -45.97% | 10.95B | |
| +3.30% | 8.85B | |
| -13.92% | 7.53B |
- Stock Market
- Equities
- BMRN Stock
